Smoking may modify the association between neoadjuvant chemotherapy and survival from XXXX .

@entity1 @entity286 @entity43 @entity66 @entity3012 @entity5
OBJECTIVE: @entity286 smoking by @entity5 @entity1 is associated with increased mortality. Less is known of the impact of smoking on recurrence risk and interaction with chemotherapy treatment. We examined these associations in @entity43 . METHODS: @entity1 were identified from the Alberta Cancer Registry between 1978 and 2010 and were oversampled for less-common histologic @entity43 types. Medical records were abstracted for 678 eligible @entity1 on lifestyle, medical and @entity5 treatment, and review of pathology slides was performed for 605 @entity1 . We estimated hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazard models adjusted for age at diagnosis, race, stage and @entity66 . RESULTS: Among @entity1 receiving adjuvant chemotherapy (N=432), current smoking was significantly associated with shorter duration of overall ( @entity3012 ; HR, 8.56; 95% CI, 1.50-48.7) and progression-free (PFS; HR, 5.74; 95% CI, 1.05-31.4) survival from mucinous @entity43 only. There was no significant association between neoadjuvant chemotherapy and survival. However, among @entity1 receiving neoadjuvant chemotherapy (N=44), current smokers had shorter PFS (HR, 4.32; 95% CI, 1.36-13.8; N=32 progressed/9 censored events) compared to never smokers, but the HRs were not statistically different across smoking categories (P interaction=0.87). CONCLUSIONS: Adverse associations were observed between smoking status and @entity3012 or PFS among @entity1 with mucinous @entity43 receiving adjuvant chemotherapy. No significant effect was found from neoadjuvant chemotherapy on PFS overall; however, smoking may modify this association. Although needing replication, these findings suggest that @entity1 may benefit from smoking cessation interventions prior to treatment with chemotherapy.
